<DOC>
	<DOCNO>NCT02075515</DOCNO>
	<brief_summary>The purpose study demonstrate lot-to-lot consistency term immunogenicity , evaluate safety Herpes Zoster subunit ( HZ/su ) vaccine . The study design randomize , double-blind study three parallel group .</brief_summary>
	<brief_title>Consistency , Immunogenicity Safety Study GlaxoSmithKline ( GSK ) Biologicals ' Herpes Zoster ( HZ ) Vaccine GSK1437173A Adults ≥ 50 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol . A male female age 50 year old time first vaccination . Written inform consent obtain subject . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . A prednisone dose &lt; 20 mg/day allow . Inhaled , topical intraarticular corticosteroid allow . Administration plan administration live vaccine period start 30 day first dose study vaccine end 30 day last dose study vaccine , , administration plan administration nonreplicating vaccine ( E.g . inactivate subunit vaccine ) within 8 day prior within 14 day either dose study vaccine . Administration longacting immunemodifying drug within six month prior first vaccine dose expect administration time study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Previous vaccination HZ varicella . Planned administration study HZ varicella vaccine study vaccine . History HZ . Any confirm suspected immunosuppressive immunodeficient condition result disease immunosuppressive/cytotoxic therapy . History reaction hypersensitivity likely exacerbate component vaccine . Acute disease and/or fever time enrollment . Fever define temperature ≥ 37.5°C ( 99.5°F ) oral , axillary tympanic route , ≥ 38.0°C ( 100.4°F ) rectal route . The preferred route record temperature study oral . Subjects minor illness without fever may enrol discretion investigator . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Pregnant lactating female . Females plan become pregnant planning discontinue contraceptive precaution ( childbearing potential ) Month 4 . Any condition , opinion investigator , prevents subject participate study . Any condition , opinion investigator , might interfere evaluation require study . Any condition , judgment investigator would make intramuscular injection unsafe .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Zoster</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Adults</keyword>
	<keyword>Consistency</keyword>
</DOC>